Plus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Cerenome

05/03/2024 23:43

* Plus Therapeutics Inc  PSTV.OQ  reported a quarterly
adjusted
loss of 84 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-3.30.  The mean expectation of four analysts
for the quarter was for a loss of $1.07 per share. Wall Street
expected results to range from $-1.91 to -77 cents per share.
    * Revenue rose 769.5% to $1.31 million from a year ago;
analysts
expected $1.06 million. 
    * Plus Therapeutics Inc's reported EPS for the quarter was a
loss
of 84 cents​.
    * The company reported a quarterly loss of $3.81 million.
    * Plus Therapeutics Inc shares had risen by 21.7% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Plus Therapeutics
Inc is $21.00 
This summary was machine generated from LSEG data March 5 at
11:43 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.07          -0.84          Beat
 Sep. 30 2023      -1.12          -1.00          Beat
 Jun. 30 2023      -1.91          -0.59          Beat
 Mar. 31 2023      -1.90          -2.10          Missed